Share Purchase Agreement (May 10th, 2011)
THIS SHARE PURCHASE AGREEMENT (this Agreement) dated as of April 18, 2011 is by and among SciClone Pharmaceuticals, Inc., a Delaware corporation (Parent), SciClone Pharmaceuticals Hong Kong Limited, a company incorporated and existing under the laws of Hong Kong and wholly-owned subsidiary of Parent (Purchaser), NovaMed Pharmaceuticals, Inc., an exempted company incorporated with limited liability under the laws of the Cayman Islands (Target), and the undersigned individuals as set forth on the signature pages hereto (each a Seller and collectively, the Sellers), and, with respect to Sections 2, 7, 9, 10 and 11, Mark Lotter as the Seller Representative.
Loan and Security Agreement (March 17th, 2008)
THIS LOAN AND SECURITY AGREEMENT, dated as of December 31, 2007 (as amended, restated, supplemented or otherwise modified from time to time (this Agreement)) is among GENERAL ELECTRIC CAPITAL CORPORATION (GECC), in its capacity as agent for Lenders (as defined below), together with its successors and assigns in such capacity, Agent), the financial institutions who are or hereafter become parties to this Agreement as lenders (together with GECC, collectively the Lenders, and each individually, a Lender), HELICOS BIOSCIENCES CORPORATION, a Delaware corporation (Borrower), and the other entities or persons, if any, who are or hereafter become parties to this Agreement as guarantors (each a Guarantor and collectively, the Guarantors, and together with Borrower, each a Loan Party and collectively, Loan Parties).
Non-Employee Director Compensation Summary (March 10th, 2008)
Momenta Pharmaceuticals, Inc.s (the Companys) non-employee directors are currently: (i) Peter Barrett; (ii) Peter Barton Hutt; (iii) Elizabeth Stoner; (iv) Bennett M. Shapiro; (v) John K. Clarke; (vi) Robert S. Langer, Jr.; (vii) Stephen T. Reeders; (viii) Ram Sasisekharan; (ix) Marsha H. Fanucci; and (x) Alan L. Crane. The compensation structure for the Companys non-employee directors as follows:
October 13, 2006 (November 8th, 2006)
As stated in your letter of August 22, 2006, your resignation from the position of President of Momenta Pharmaceuticals, Inc. (hereafter, Momenta or the Company) occurred on that date and your resignation from the position of Chief Executive Officer for the Company became effective September 12, 2006. However, you are and shall continue to serve as a member of the Companys Board of Directors in accordance with the Companys By-Laws and you shall have all rights, responsibilities and privileges (including insurance coverage and other protections) associated therewith. In recognition of your many contributions to the Company, the Company will pay you the severance benefits described in the Description of Severance Benefits attached as Attachment A if you timely sign and return this letter agreement to Lisa Carron Shmerling, V.P., Legal Affairs of the Company, by November 4, 2006. By signing and returning this letter agreement, you will be agreeing to the terms and conditions set forth
Non-Employee Director Compensation Summary (March 16th, 2006)
Momenta Pharmaceuticals, Inc.s (the Companys) non-employee directors are currently: (i) Peter Barrett; (ii) Peter Barton Hutt; (iii) Christoph H. Westphal; (iv) Bennett M. Shapiro; (v) John K. Clarke; (vi) Robert S. Langer, Jr.; (vii) Stephen T. Reeders; (viii) Ram Sasisekharan; and (ix) Marsha H. Fanucci. On March 7, 2006, the Companys Board of Directors (the Board) approved a revised compensation structure for the Companys non-employee directors as follows:
Contract (March 31st, 2005)
EXHIBIT 10.49 NON-EMPLOYEE DIRECTOR COMPENSATION SUMMARY Momenta Pharmaceuticals, Inc.'s (the "Company's") non-employee directors currently consist of: (i) Peter Barton Hutt; (ii) Christopher H. Westphal; (iii) Bennett M. Shapiro; (iii) John K. Clarke; (iv) Robert S. Langer, Jr.; (v) Stephen T. Reeders; (vi) Peter Barrett; (vii) Ram Sasisekharan; and (viii) Marsha Fanucci. NON-EMPLOYEE DIRECTOR COMPENSATION FOR 2004 In April 2004, the Company's Board of Directors approved a compensation program pursuant to which each non-employee director would automatically receive an option to purchase no more than 38,400 shares of the Company's common stock upon his or her appointment to the Company's Board of Directors. These options vest to the extent of one-third of the shares on each of the first, second and third anniversaries of the grant date, subject to the non-employee director's continued service as a director. Subject to an annual evaluation, which evaluat